Currently no disease-modifying or neuroprotective treatments exist for MSA, nor are there effective medications to treat the cerebellar ataxia in MSA-C or the parkinsonian features in MSA-P. Physical ...

Four patients with Unified Multiple System Atrophy Rating Scale (UMSARS) ≤20 points at baseline were allocated to the moderate stage group. Four patients with UMSARS > 20 points at baseline were ...

Background Multiple system atrophy (MSA) is a progressive neurodegenerative disorder of unknown etiology, manifesting as combination of parkinsonism, cerebellar syndrome and dysautonomia.

MELBOURNE, Australia and SAN FRANCISCO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...

"Multiple System Atrophy Competitive Landscape"Multiple System Atrophy companies are Neuramedy Co.,Ltd, ProMIS Neurosciences, Enterin Inc., Nippon Chemiphar, CORESTEM ...

White arrows indicate accumulation of 18F-SPAL-T-06, suggesting α-synuclein aggregates in the putamen, yellow arrows in the pons, yellow triangle in the cerebellar white matter, and white triangle in ...

Teva received Fast Track designation from the U.S. Food and Drug Administration for emrusolmin (TEV-56286), an investigational treatment for Multiple System Atrophy (MSA) in Phase 2 development. New ...

Multiple sclerosis (MS) affects an estimated 2.3 million people worldwide. Approximately 80% of people with MS have inflammation in the cerebellum, the part of the brain that helps control movement ...

This was a single-arm, interventional-, single-center, open-label prospective study. Patients with a history of probable MSA [15] were enrolled in the study (Table 1). All patients had some ...